$1.63
+0.01 (+0.62%)
Open$1.63
Previous Close$1.62
Day High$1.65
Day Low$1.61
52W High$3.35
52W Low$1.34
Volume—
Avg Volume51.3K
Market Cap80.65M
P/E Ratio—
EPS$-0.11
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,672.4% upside
Current
$1.63
$1.63
Target
$28.89
$28.89
$16.92
$28.89 avg
$30.86
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.01M | 9.02M | 8.76M |
| Net Income | -596,230 | -528,269 | -565,775 |
| Profit Margin | -6.6% | -5.9% | -6.5% |
| EBITDA | -746,119 | -716,524 | -642,558 |
| Free Cash Flow | -600,890 | -503,274 | -433,552 |
| Rev Growth | +12.0% | +12.6% | +22.9% |
| Debt/Equity | 0.77 | 0.69 | 0.70 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |